Get the full picture
Sign in to uncover key details.
Primmune Therapeutics
Manufacturing · California, United States · 1-10 Employees
View Company Info for Free
Overview
Headquarters
Jlabs 3210 San Diego, San Diego, Califor...Phone Number
(858) 205-2281Website
www.primmunerx.comRevenue
<$5 MillionIndustry
About Primmune Therapeutics
Primmune Therapeutics is a clinical-stage biotechnology company headquartered in San Diego, USA, focused on developing orally administered small-molecule immunotherapies that harness innate immunity to improve cancer and viral disease treatment. Its lead investigational candidate, PRTX007, is designed to activate key immune pathways without triggering broad inflammatory responses, aiming to enhance antitumor immunity and complement existing therapies while advancing through clinical studies.Explore more
Primmune Therapeutics Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Compare Similar Companies to Primmune Therapeutics
Compare insights from companies similar to Primmune Therapeutics, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Primmune Therapeutics
<$5M
1-10
Private
$61.7M
2017
Stephen WebberCo-Founder & Vice President, Medicinal Chemistry
Primmune Therapeutics Tech Stack
A closer look at the technologies used by Primmune Therapeutics
See more technologies
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Primmune Therapeutics
Sign Up For FreeTo access detailed company insights
Primmune Therapeutics is a clinical-stage biotechnology company headquartered in San Diego, USA, focused on developing orally administered small-molecule immunotherapies that harness innate immunity to improve cancer and viral disease treatment. Its lead investigational candidate, PRTX007, is designed to activate key immune pathways without trigger... Read More
